According to the connectivity score (< − 0.3), different treatment doses of geldanamycin and different time points of geldanamycin administration were suitable for targeting the oncogenic pattern seen in gastric, colorectal, and lung cancer cell lines in which PIK3CA + HMCN1 comutation was the marginal factor and the seed mutation was in LRP1B. However, the TAS should be greater than 0.2 (Fig. 5c, Supplementary Table 6). This evidence concerns the gene HMCN1 and lung cancer.